Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
William Edward Evans, Mary V. Relling · Science · 1999
Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications. Pharmacogenomic studies are rapidly elucidating the inherited nature of these differences in drug disposition and effects, thereby enhancing drug discovery and providing a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.
Cited by 2,475 works. doi:10.1126/science.286.5439.487
Authors
References
- Space-Time Relationships in Somesthetic Localization
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
- Medical and Ethical Consequences of the Human Genome Project
- Acute Lymphoblastic Leukemia
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
- Genetic Control of Isoniazid Metabolism in Man
- MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
- Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes